Risk factors for mortality in patients with ventilator-associated pneumonia caused by carbapenem-resistant Enterobacteriaceae

Brazilian Journal of Infectious Diseases

Volumn 21, Issue 1, 2017, Pages 1-6

  Tuon, Felipe F ^a,b   Graf, Maria Esther ^a,c   Merlini, Alexandre ^b   Rocha, Jaime L ^a,d   Stallbaum, Suellen ^b   Arend, Lavinia N ^e   Pecoit Filho, Roberto ^a  

^a PONTIFICAL CATHOLIC UNIVERSITY OF PARANÁ   (Brazil)

^b HOSPITAL UNIVERSITÁRIO EVANGÉLICO DE CURITIBA   (Brazil)

^c HOSPITAL UNIVERSITÁRIO CAJURU   (Brazil)

^d Frischmann Aisengart DASA Medicina Diagnóstica and VITA Curitiba Hospital   (Brazil)

^e Paraná s Central Laboratory LACEN PR   (Brazil)

Author keywords

Carbapenemase producing Klebsiella pneumoniae; Mortality; Risk factors; Treatment; Ventilator associated pneumonia

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; CARBAPENEM; COLISTIN; ERTAPENEM; MEROPENEM; POLYMYXIN B; TIGECYCLINE; ANTIINFECTIVE AGENT; CARBAPENEM DERIVATIVE;

ADULT; AGE; ANTIBIOTIC SENSITIVITY; APACHE; ARTICLE; ARTIFICIAL VENTILATION; BURN; CARBAPENEM RESISTANT ENTEROBACTERIACEAE; CHARLSON COMORBIDITY INDEX; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DNA SEQUENCE; ELECTIVE SURGERY; EMERGENCY SURGERY; ENTEROBACTER AEROGENES; FEMALE; HOSPITAL ADMISSION; HOSPITAL MORTALITY; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INJURY; KLEBSIELLA PNEUMONIAE; LOGISTIC REGRESSION ANALYSIS; LUNG LAVAGE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY RATE; REPEATED DRUG DOSE; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL RATE; SURVIVOR; TERTIARY CARE CENTER; VENTILATOR ASSOCIATED PNEUMONIA; AGED; ANTIBIOTIC RESISTANCE; COMBINATION DRUG THERAPY; DRUG EFFECTS; ENTEROBACTERIACEAE INFECTION; MICROBIOLOGY; MORTALITY; NONPARAMETRIC TEST; PNEUMONIA, VENTILATOR-ASSOCIATED; STATISTICAL MODEL; TIME FACTOR; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CARBAPENEMS; CROSS-SECTIONAL STUDIES; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; ENTEROBACTER AEROGENES; ENTEROBACTERIACEAE INFECTIONS; FEMALE; HOSPITAL MORTALITY; HUMANS; KLEBSIELLA PNEUMONIAE; LOGISTIC MODELS; MALE; MIDDLE AGED; PNEUMONIA, VENTILATOR-ASSOCIATED; RETROSPECTIVE STUDIES; RISK FACTORS; STATISTICS, NONPARAMETRIC; TIME FACTORS; TREATMENT OUTCOME;

EID: 85008195211     PISSN: 14138670     EISSN: 16784391     Source Type: Journal    
DOI: 10.1016/j.bjid.2016.09.008     Document Type: Article

References (22)

1. 1 Nordmann, P., Naas, T., Poirel, L., Global spread of Carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis 17 (2011), 1791–1798.
2. 2 Tumbarello, M., Viale, P., Viscoli, C., et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis 55 (2012), 943–950.
3. 3 Toledo, P.V., Tuon, F.F., Arend, L., Aranha Junior, A.A., Efficacy of tigecycline, polymyxin, gentamicin, meropenem and associations in experimental Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae non-lethal sepsis. Braz J Infect Dis 18 (2014), 574–583.
4. 4 Lat, A., Clock, S.A., Wu, F., et al. Comparison of polymyxin B, tigecycline, cefepime, and meropenem MICs for KPC-producing Klebsiella pneumoniae by broth microdilution, Vitek 2, and Etest. J Clin Microbiol 49 (2011), 1795–1798.
5. 5 Castanheira, M., Sader, H.S., Jones, R.N., Antimicrobial susceptibility patterns of KPC-producing or CTX-M-producing Enterobacteriaceae. Microb Drug Resist 16 (2010), 61–65.
6. 6 Tuon, F.F., Rocha, J.L., Formighieri, M.S., et al. Fosfomycin susceptibility of isolates with blaKPC-2 from Brazil. J Infect 67 (2013), 247–249.
7. 7 Toledo, P.V., Arend, L.N., Pilonetto, M., Costa Oliveira, J.C., Luhm, K.R., Working Group in Healthcare Associated I. Surveillance programme for multidrug-resistant bacteria in healthcare-associated infections: an urban perspective in South Brazil. J Hosp Infect 80 (2012), 351–353.
8. 8 Ribeiro, V.B., Andrade, L.N., Linhares, A.R., et al. Molecular characterization of Klebsiella pneumoniae carbapenemase-producing isolates in southern Brazil. J Med Microbiol 62:Pt 11 (2013), 1721–1727.
9. 9 Maltezou, H.C., Giakkoupi, P., Maragos, A., et al. Outbreak of infections due to KPC-2-producing Klebsiella pneumoniae in a hospital in Crete (Greece). J Infect 58 (2009), 213–219.
10. 10 Kontopidou, F., Giamarellou, H., Katerelos, P., et al. Infections caused by carbapenem-resistant Klebsiella pneumoniae among patients in intensive care units in Greece: a multi-centre study on clinical outcome and therapeutic options. Clin Microbiol Infect 20 (2014), O117–O123.
11. 11 Daly, M.W., Riddle, D.J., Ledeboer, N.A., Dunne, W.M., Ritchie, D.J., Tigecycline for treatment of pneumonia and empyema caused by carbapenemase-producing Klebsiella pneumoniae. Pharmacotherapy 27 (2007), 1052–1057.
12. 12 Tuon, F.F., Gortz, L.W., Penteado-Filho, S.R., Soltoski, P.R., Hayashi, A.Y., Miguel, M.T., Bacteriological study of bronchoalveolar lavage in the antibiotic management of suspected ventilator-associated pneumonia of patients in surgical intensive care units. Rev Col Bras Cir 39 (2012), 353–357.
13. 13 CLSI (Clinical Laboratory Standard Institute), Performance standard for antimicrobial susceptibility testing; Twenty-third informational supplement. 2013.
14. 14 Tuon, F.F., Rocha, J.L., Toledo, P., et al. Risk factors for KPC-producing Klebsiella pneumoniae bacteremia. Braz J Infect Dis 16 (2012), 416–419.
15. 15 Horan, T.C., Andrus, M., Dudeck, M.A., CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 36 (2008), 309–332.
16. 16 Charlson, M.E., Pompei, P., Ales, K.L., MacKenzie, C.R., A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40 (1987), 373–383.
17. 17 Knaus, W.A., Draper, E.A., Wagner, D.P., Zimmerman, J.E., APACHE II: a severity of disease classification system. Crit Care Med 13 (1985), 818–829.
18. 18 Jones, R.N., Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Clin Infect Dis 51:Suppl. 1 (2010), S81–S87.
19. 19 Qureshi, Z.A., Paterson, D.L., Potoski, B.A., et al. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Chemother 56 (2012), 2108–2113.
20. 20 Gasink, L.B., Edelstein, P.H., Lautenbach, E., Synnestvedt, M., Fishman, N.O., Risk factors and clinical impact of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. Infect Control Hosp Epidemiol 30 (2009), 1180–1185.
21. 21 Paul, M., Carmeli, Y., Durante-Mangoni, E., et al. Combination therapy for carbapenem-resistant Gram-negative bacteria. J Antimicrob Chemother 69 (2014), 2305–2309.
22. 22 Sun, H.K., Kuti, J.L., Nicolau, D.P., Pharmacodynamics of antimicrobials for the empirical treatment of nosocomial pneumonia: a report from the OPTAMA Program. Crit Care Med 33 (2005), 2222–2227.